Evidence map›Paper›PMID 41459930›Full record

ArticleAntimicrobial agents and chemotherapy2026

A stochastic simulation-based approach to inform the relapsing mouse model study design for non-clinical assessment of tuberculosis.

James Clary, Jessica K Roberts, Debra Hanna, Alessia Tagliavini, Sylvie Sordello, Anna Upton, David Hermann, Alexander Berg

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

James ClarySimulations Plus, Inc., Lancaster, California, USA.
Jessica K RobertsSimulations Plus, Inc., Lancaster, California, USA.
Debra HannaGates Foundation, Seattle, Washington, USA.
Alessia TagliaviniPharmacometrics, Aptuit (an Evotec Company), Verona, Italy.
Sylvie SordelloTranslational Biology, Infection Diseases, Evotec France, Toulouse, France.ORCID 0009-0003-0507-6792
Anna UptonEvotec USA Inc., Princeton, New Jersey, USA.
David HermannGates Foundation, Seattle, Washington, USA.
Alexander BergSimulations Plus, Inc., Lancaster, California, USA.ORCID 0000-0001-7781-0755

Funding

Bill and Melinda Gates Foundation INV-060170
6 · The paper itself

Abstract

The development of new regimens to treat tuberculosis (TB), the disease caused by

Indexed as

Antitubercular AgentsMycobacterium tuberculosisTuberculosisAnimalsComputer SimulationDisease Models, AnimalMiceRecurrenceResearch DesignStochastic ProcessesAntitubercular Agentsmodeling & simulationrelapsing mouse modelstudy designtuberculosis

Identifiers

PMID41459930
PMCPMC12888889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.